Residual risk seen for death, postacute sequelae in third year after COVID-19 hospitalization
Jun 13, 2024
The risk for death remains significantly elevated in the third year, as is risk for incident postacute sequelae of COVID-19.
Systemic side effects of COVID-19 vaccine tied to greater nAB response
Jun 11, 2024
Each 1-degree Celsius increase in skin temperature after a dose was linked to a 1.8- and 3.1-fold higher neutralizing antibody response one and six months later.
Nirmatrelvir-ritonavir no aid for long COVID symptoms
Jun 10, 2024
The findings based on symptoms at 10 weeks following 15-day course in vaccinated cohort.
No decline in cardiovascular events seen with COVID-19 vaccine after acute coronary syndromes
Jun 03, 2024
Findings show no significant reduction in primary end point, MACE for those receiving vaccine after acute coronary syndromes
Mortality higher for COVID-19 hospitalization than for flu in 2023/2024 season
May 22, 2024
The authors highlight that the volume of hospitalizations for COVID-19 was double that of the volume for flu.
Identifying highest-risk assisted living communities key to tackling next outbreak: report
By
Kimberly Bonvissuto
May 22, 2024
The public health response to COVID-19 in assisted living communities in New York highlights the need to identify those communities at highest risk of infectious disease outbreaks to provide necessary...
Long COVID definitions, care models are evolving
May 20, 2024
Care models are informed by five key principles, including multidisciplinary expertise and a patient-centered approach.
Following drop after COVID-19 onset, inappropriate antibiotic prescribing is up
May 01, 2024
An initial decrease was seen in proportion with inappropriate prescription, followed by a subsequent increase.
Long-term smell, but not taste, deficits seen after COVID-19
May 01, 2024
The deficits appear to be the greatest for individuals with the original untyped and alpha variant infections.
SARS-CoV-2 vaccine does not increase new-onset seizure risk
Apr 30, 2024
The findings compared with placebo at 28-day and 43-day follow-up.